🫀 Semaglutide Reduces Hospital Admissions in Patients with Obesity and CVD: SELECT Trial Analysis

🧪 What was studied: Exploratory analysis of the SELECT RCT (n=17,604, adults ≥45 years with established CVD and BMI ≥27, non-diabetic) comparing once-weekly semaglutide 2.4mg vs placebo for hospitalizations.

📈 Key results: Semaglutide reduced all-cause hospitalizations (18.3 vs 20.4 per 100 pt-yrs, mean ratio 0.90, 95% CI 0.85-0.95, P<.001), days in hospital (rate ratio 0.89, 95% CI 0.82-0.98), and serious adverse event admissions (MR 0.89; P<.001). No subgroup heterogeneity.

📍 What this changes in practice: In elderly, overweight/obese patients with CVD, semaglutide not only provides CV risk reduction but also decreases total hospital admissions and days in hospital—strengthening its case as a disease-modifying therapy in high-risk metabolic populations.

🔗 Source: PubMed | DOI

🧪 GLP-1RA Use During Cancer Immunotherapy—Lower Mortality & irAEs, Caution for Retinopathy

🔥 Main in 3 points

• GLP-1RAs at ICI initiation lowered all-cause mortality (HR 0.55, NNT=5) and immune-related adverse events in adults with T2D and cancer.
• Hospitalization and irAEs dropped significantly, but retinopathy progression (HR 1.75) and ischemic optic neuropathy risk were higher.
• Semaglutide-only and sensitivity analyses confirm robustness; AKI/hypoglycemia risk lower.

🧪 Context: Target-trial emulation, 2,903 T2D patients with cancer/ICI per group, 36-month follow-up, propensity matched.

📍 Practical significance: For diabetic cancer patients starting ICIs, GLP-1RA co-therapy (including semaglutide) may yield mortality and morbidity benefits, but warrants vigilant ophthalmic monitoring for retinopathy.

🔗 Source: PubMed | DOI

⚠️ Bezoar-Induced Small Bowel Obstruction Linked to Semaglutide-Induced Gastroparesis

🧪 Context: Case report: 65-year-old woman using semaglutide for weight loss developed acute small bowel obstruction from a phytobezoar, requiring surgical intervention.

📊 Numbers: No incidence provided; highlights qualitative risk.

📍 Actions: For patients on semaglutide (and other GLP-1RAs) who present with GI symptoms or obstruction, consider gastroparesis and bezoar as potential causes. Monitor for bowel motility issues, especially during dose escalation.

🔗 Source: PubMed | DOI

🧾 Perioperative Management of GLP-1RA (semaglutide) in Elective Surgery

✅ Do

• Discontinue weekly semaglutide or dulaglutide ≥1 week before surgery.
• For oral semaglutide, stop 24–48 hours pre-op.
• Proactively assess for delayed gastric emptying, especially with GI symptoms.

⚠️ With caution

• Watch for residual gastric content and aspiration risk; may persist despite fasting.
• Anticipate higher risk during dose escalation or when GI AEs are present.

🚫 Avoid

• Rushed reinitiation of GLP-1RA in immediate post-op period.

🔗 Source: PubMed | DOI

🧠 Semaglutide & Alzheimer’s Disease: Mechanistic Insights and Ongoing Trials

🔥 Main in 3 points

• Semaglutide crosses BBB, reduces neuroinflammation, amyloid, and tau burden in preclinical/early human data.
• Observational studies suggest lower AD risk in T2D patients on semaglutide; Phase 3 EVOKE trial will clarify efficacy.
• Mechanistic evidence links improved brain insulin resistance (IRS-1pS616 pathology) to semaglutide’s neuroprotective potential.

🧪 Context: Systematic reviews and translational studies; target population—patients with neurodegeneration/metabolic syndrome.

📍 Practical significance: No indication for semaglutide in AD yet, but evidence base rapidly emerging; monitor for publication of outcome RCTs in 2025–26.

🔗 Sources:

PMID: 41439359 | DOI: 10.1002/alz70855_103762

PMID: 41445510 | DOI: 10.1002/alz70855_106242

🧪 Perioperative GLP-1RA Therapy Lowers Hip Infection & Readmission After Arthroplasty

🧪 What was studied: Meta-analysis of 8 observational cohorts; adults with obesity undergoing hip/knee arthroplasty, GLP-1RA users (n=22,098) vs non-users (total n=95,503).

📈 Key results: GLP-1RA exposure reduced periprosthetic joint infection (hip surgery; ARR 1.8%, NNT=56) and 90-day readmissions. No signal for excess VTE, AKI, MI, or hypoglycemia.

📍 What this changes in practice: In obese patients considered for hip arthroplasty, perioperative GLP-1RAs may improve infection/readmission outcomes without acute vascular risk increase. More RCTs needed for knee procedures.

🔗 Source: PubMed | DOI